Business
Bright Minds Biosciences Inc. to Webcast Live At VirtualInvestorConferences.com October 14th
Bright Minds Biosciences Inc. to Webcast Live At VirtualInvestorConferences.com October 1...
About this update from Bright Minds Biosciences Inc.
[{"type":"text","content":"\n \n \n \n Bright Minds Biosciences Inc. to Webcast Live At VirtualInvestorConferences.com October 14th\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com\n \n \n PR Newswire\n \n \n \n \n \n NEW YORK\n \n ,\n \n Oct. 7, 2021\n \n /PRNewswire/ --\n \n BRIGHT MINDS BIOSCIENCES INC.\n \n (CSE: DRUG/OTCIQ: BMBIF), based in\n \n New York\n \n focused on new approaches to neuroscience, today announced that\n \n Ian McDonald\n \n , President & CEO and\n \n Josh Blacher\n \n , VP of Corporation Development, will present live at VirtualInvestorConferences.com on\n \n October 14\n \n \n th\n \n .\n \n \n \n \n \n \n \n \n \n \n DATE:\n \n October 14\n \n \n th\n \n , 2021\n \n \n \n TIME: 11:00 –\n \n 11:30 AM ET\n \n \n \n \n LINK:\n \n \n \n https://bit.ly/3kObcQO\n \n \n \n \n This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.\n \n \n It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates.\n \n \n Learn more about the event at\n \n www.virtualinvestorconferences.com\n \n .\n \n \n \n Recent Company Highlights\n \n \n \n \n Lead program, BMB-101, advances to IND-enabling toxicology studies with the aim of commencing human trials in 1H 2022\n \n \n Bright Minds Biosciences (\"BMB\") Proprietary 5-HT2C Agonist Shows Significant Reduction in Seizure Activity\n \n \n Bright Minds Biosciences Announces Application to List on Nasdaq\n \n \n \n \n \n About BRIGHT MINDS BIOSCIENCES INC.\n \n \n \n \n Bright Minds is a biotechnology company dedicated to developing therapeutics to improve the lives of patients with severe and life–altering diseases. Bright Minds initially focused on new chemical entities for...